NASDAQ:KOD Kodiak Sciences (KOD) Stock Price, News & Analysis $36.22 +1.80 (+5.23%) Closing price 04:00 PM EasternExtended Trading$36.24 +0.02 (+0.04%) As of 06:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Kodiak Sciences Stock (NASDAQ:KOD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Kodiak Sciences alerts:Sign Up Key Stats Today's Range$34.49▼$36.4350-Day Range$21.85▼$46.4452-Week Range$3.26▼$47.84Volume665,331 shsAverage Volume951,027 shsMarket Capitalization$2.27 billionP/E RatioN/ADividend YieldN/APrice Target$42.14Consensus RatingModerate Buy Company Overview Kodiak Sciences, Inc. is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company’s proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak’s research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders. The lead product candidate in Kodiak’s pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection. KSI-301 is engineered to achieve extended drug exposure in retinal tissue, with the goal of reducing treatment burden for patients by prolonging the interval between dosing. In addition to KSI-301, the company is advancing KSI-501, an anti-IL-6 receptor bioconjugate, which is being evaluated for its potential to address both VEGF-mediated and inflammatory pathways in retinal disease. Founded in 2015 under the name Oligome and rebranded as Kodiak Sciences in 2017, the company completed its initial public offering on the Nasdaq in mid-2017. Kodiak has since built a team of experienced drug developers, regulatory specialists and clinicians to support its clinical programs. Robert R. Burke serves as President and Chief Executive Officer, bringing over two decades of leadership in biotechnology and pharmaceutical research to guide the company’s strategic direction. Kodiak Sciences conducts its clinical trials primarily in the United States, with select international sites to support global patient enrollment. The company maintains collaborations and partnerships to bolster its research efforts and aims to establish long-term value through the advancement of its ABC platform. Kodiak continues to expand its clinical and regulatory capabilities as it moves toward pivotal studies and potential regulatory filings for its lead candidates.AI Generated. May Contain Errors. Read More Kodiak Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks39th Percentile Overall ScoreKOD MarketRank™: Kodiak Sciences scored higher than 39% of companies evaluated by MarketBeat, and ranked 652nd out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingModerate Buy Consensus RatingKodiak Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialKodiak Sciences has a consensus price target of $42.14, representing about 16.4% upside from its current price of $36.22.Amount of Analyst CoverageKodiak Sciences has only been the subject of 3 research reports in the past 90 days.Read more about Kodiak Sciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Kodiak Sciences are expected to grow in the coming year, from ($3.89) to ($3.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kodiak Sciences is -8.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kodiak Sciences is -8.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKodiak Sciences has a P/B Ratio of 20.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted30.27% of the float of Kodiak Sciences has been sold short.Short Interest Ratio / Days to CoverKodiak Sciences has a short interest ratio ("days to cover") of 17.45, which indicates bearish sentiment.Change versus previous monthShort interest in Kodiak Sciences has recently decreased by 0.71%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKodiak Sciences does not currently pay a dividend.Dividend GrowthKodiak Sciences does not have a long track record of dividend growth. News and Social Media2.3 / 5News Sentiment0.76 News SentimentKodiak Sciences has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Kodiak Sciences this week, compared to 5 articles on an average week.Search InterestOnly 2 people have searched for KOD on MarketBeat in the last 30 days. This is a decrease of -92% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Kodiak Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Kodiak Sciences insiders have not sold or bought any company stock.Percentage Held by Insiders45.90% of the stock of Kodiak Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions89.06% of the stock of Kodiak Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Kodiak Sciences' insider trading history. Receive KOD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kodiak Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KOD Stock News HeadlinesKodiak Sciences Inc. (NASDAQ:KOD) Receives $42.14 Consensus Target Price from BrokeragesMay 19 at 3:27 AM | americanbankingnews.comWhy One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping RallyMay 17 at 5:28 PM | fool.comThe chokepoint supplier behind SpaceX's $1.75 trillion empireWhen Musk laughed and said 'you need transformers to run transformers,' it wasn't a joke - it was a confession. The world's largest supercomputer requires power equipment that takes 120 weeks to build, and Musk built Colossus in just 122 days. One small American company is positioned to close that gap faster than anyone else, yet Wall Street still prices it like an afterthought. Dylan Jovine has the full story and the ticker.May 20 at 1:00 AM | Behind the Markets (Ad)Wall Street Zen Upgrades Kodiak Sciences (NASDAQ:KOD) to "Hold"May 16, 2026 | americanbankingnews.comKodiak Sciences (KOD) price target increased by 16.91% to 66.30May 14, 2026 | msn.comKodiak Sciences (NASDAQ:KOD) Rating Increased to Buy at Chardan CapitalMay 12, 2026 | americanbankingnews.comChardan Capital upgrades Kodiak Sciences (KOD)May 11, 2026 | msn.comA Look At Kodiak Sciences (KOD) Valuation After Positive Phase 3 GLOW2 Results For ZenkudaMay 11, 2026 | finance.yahoo.comSee More Headlines KOD Stock Analysis - Frequently Asked Questions How have KOD shares performed this year? Kodiak Sciences' stock was trading at $27.96 at the beginning of the year. Since then, KOD shares have increased by 29.5% and is now trading at $36.22. How were Kodiak Sciences' earnings last quarter? Kodiak Sciences Inc. (NASDAQ:KOD) posted its earnings results on Thursday, May, 7th. The company reported ($0.94) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.93) by $0.01. When did Kodiak Sciences IPO? Kodiak Sciences (KOD) raised $126 million in an initial public offering on Thursday, October 4th 2018. The company issued 9,000,000 shares at $13.00-$15.00 per share. Morgan Stanley and BofA Merrill Lynch acted as the underwriters for the IPO and Barclays and Chardan were co-managers. Who are Kodiak Sciences' major shareholders? Top institutional shareholders of Kodiak Sciences include Janus Henderson Group PLC (2.12%), Dimensional Fund Advisors LP (0.51%), Bank of America Corp DE (0.48%) and Renaissance Technologies LLC (0.47%). Insiders that own company stock include Bros Advisors Lp Baker, John A Borgeson and Jason Ehrlich. View institutional ownership trends. How do I buy shares of Kodiak Sciences? Shares of KOD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Kodiak Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kodiak Sciences investors own include NVIDIA (NVDA), Datadog (DDOG), CrowdStrike (CRWD), Tesla (TSLA), Meta Platforms (META), Advanced Micro Devices (AMD) and Splunk (SPLK). Company Calendar Last Earnings5/07/2026Today5/20/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (13m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 KOD's financial health is in the Green zone, according to TradeSmith. KOD has been in this zone for over 13 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KOD CIK1468748 Webkodiak.com Phone(650) 281-0850FaxN/AEmployees90Year Founded2009Price Target and Rating Average Price Target for Kodiak Sciences$42.14 High Price Target$80.00 Low Price Target$15.00 Potential Upside/Downside+16.4%Consensus RatingModerate Buy Rating Score (0-4)2.63 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($4.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$229.97 million Net MarginsN/A Pretax MarginN/A Return on Equity-253.85% Return on Assets-81.48% Debt Debt-to-Equity RatioN/A Current Ratio3.54 Quick Ratio3.54 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.79 per share Price / Book20.23Miscellaneous Outstanding Shares62,578,000Free Float33,855,000Market Cap$2.27 billion OptionableOptionable Beta2.32 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:KOD) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredFed story no one is tellingJ.P. Morgan's Private Bank quietly advised 333 billionaire families to move 60% of their portfolios into alter...TradeSmith | SponsoredOne page of the SpaceX S-1 will move this stock overnightWhen SpaceX files its S-1 in June, the SEC will require full disclosure of operating expenses - including powe...Behind the Markets | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredThis same-day trade is getting a lot of attentionZero-days-to-expiration trades happen every single day - and most traders either ignore them or use them wrong...Base Camp Trading | SponsoredThe sell discipline that changed my mind after 30 yearsPorter Stansberry spent 30 years ignoring outside investment systems - until he met Emmet Savage in Dublin. Sa...Porter & Company | SponsoredMemorial Day Event: Save 79% on Weiss Ratings Plus!Elon Musk calls it 'mind-blowing.' Fox News calls the scramble for it 'the new arms race.' Chris Graebe, Chief...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kodiak Sciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kodiak Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
